June 13, 2024
1 min watch
Save
VIDEO: Data show positive effect of Axpaxli for wet AMD at 36 weeks
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Anat Loewenstein, MD, of Tel Aviv Medical Center in Israel, discusses Axpaxli for the treatment of neovascular age-related macular degeneration.
Loewenstein highlights phase 1 and phase 2 data for Axpaxli (axitinib intravitreal implant, Ocular Therapeutix) collected in the U.S. and Australia.
“This inhibitor was able to hold patients rescue-free for as long as 36 weeks,” she said.
Published by:
Sources/Disclosures
Collapse
Source:
Loewenstein A. Clinical update on Axpaxli for nAMD. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Disclosures:
Loewenstein reports being a consultant and a member of the scientific advisory board for Ocular Therapeutix.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.